Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)

• Company Description    Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO. Number of Employees: 385

• Price / Volume Information    Yesterday's Closing Price: $25.00 Daily Weekly Monthly 20 Day Moving Average: 2,571,546 shares Shares Outstanding: 89.14 (millions) Market Capitalization: $2,228.47 (millions) Beta: 0.79 52 Week High: $28.69 52 Week Low: $12.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 37.14% 34.66% 12 Week 73.49% 57.51% Year To Date 43.51% 28.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3611 VALLEY CENTRE DR SUITE 300 - SAN DIEGO,CA 92130 USA ph: 888-969-7879 fax: 302-645-1280 ir@travere.com https://travere.com

• General Corporate Information    Officers Eric Dube - Chief Executive Officer Gary Lyons - Chairman Christopher Cline - Chief Financial Officer Sandra Calvin - Senior Vice President and Chief Accounting Officer Roy D. Baynes - Director Peer Information Travere Therapeutics, Inc. (CORR.) Travere Therapeutics, Inc. (RSPI) Travere Therapeutics, Inc. (CGXP) Travere Therapeutics, Inc. (BGEN) Travere Therapeutics, Inc. (GTBP) Travere Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89422G107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/30/25 Share - Related Items Shares Outstanding: 89.14 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $2,228.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 67.80 Price/Cash Flow: - Price / Sales: 6.67 EPS Growth vs. Year Ago Period: 84.44% vs. Previous Quarter: 70.21% Sales Growth vs. Year Ago Period: 111.49% vs. Previous Quarter: 40.03% ROE 06/30/25 - -717.68 03/31/25 - -1,179.73 12/31/24 - -1,088.35 ROA 06/30/25 - -30.69 03/31/25 - -41.10 12/31/24 - -55.44 Current Ratio 06/30/25 - 2.00 03/31/25 - 2.05 12/31/24 - 2.08 Quick Ratio 06/30/25 - 1.98 03/31/25 - 2.03 12/31/24 - 2.04 Operating Margin 06/30/25 - -50.62 03/31/25 - -82.58 12/31/24 - -137.51 Net Margin 06/30/25 - -50.64 03/31/25 - -82.88 12/31/24 - -137.90 Pre-Tax Margin 06/30/25 - -50.65 03/31/25 - -82.60 12/31/24 - -137.46 Book Value 06/30/25 - 0.37 03/31/25 - 0.37 12/31/24 - 0.76 Inventory Turnover 06/30/25 - 2.02 03/31/25 - 1.94 12/31/24 - 1.34 Debt-to-Equity 06/30/25 - 9.50 03/31/25 - 9.46 12/31/24 - 5.25 Debt-to-Capital 06/30/25 - 90.47 03/31/25 - 90.44 12/31/24 - 84.01

Powered by Zacks Investment Research ©